Faculty profile

Alina Lalani

Back to faculty

Adjunct LecturerUniversity of Toronto

Alina Lalani

Adjunct Lecturer

Leslie Dan Faculty of Pharmacy

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Adjunct, part-time and visiting faculty usually co-supervise alongside a core faculty member.
130 publications in the last five years, latest in 2026.
Senior (last) author on 13 recent papers, a sign of leading a research group.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

201

Publications

3,016

Citations

Collaborators

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Latest papers

Association Between Sociodemographic Marginalization and Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer: Population-Based Cohort Study in Ontario, Canada.
JCO Oncology Practice · 2026
Use of concomitant G-CSF in maintaining efficacious dose and safe delivery of docetaxel in combination with darolutamide in ARASENS: A phase III study
European Journal of Cancer · 2026 · senior author
Comparing NCCN-based risk groups to the PROTEUS definition of high-risk localized prostate cancer to inform peri-operative care.
Journal of Clinical Oncology · 2026

All 201 publications

From the 150 most recent of 201 publications.

Association Between Sociodemographic Marginalization and Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer: Population-Based Cohort Study in Ontario, Canada.

Nguyen D-D, Satkunasivam R, Aminoltejari K, Hird A, Roy S, Morgan SC, Shayegan B, Kulkarni GS, Trinh Q-D, Rosella LC

JCO Oncology Practice20262 citations

DOI: 10.1200/op-25-00766

Use of concomitant G-CSF in maintaining efficacious dose and safe delivery of docetaxel in combination with darolutamide in ARASENS: A phase III study

Ong M, Suzuki H, Smith M, Tombal B, Hussain M, Saad F, Fizazi K, Verholen F, Pham H, Srinivasan S

European Journal of Cancer20262 citationsSenior authorOpen Access

DOI: 10.1016/j.ejca.2026.116264

Comparing NCCN-based risk groups to the PROTEUS definition of high-risk localized prostate cancer to inform peri-operative care.

Wallis CJD, Nguyen D-D, Shayegan B, Lalani A-KA, Gotto G, Hird AE, Kokorovic A, Huynh MJ, Feifer A, Rendon R

Journal of Clinical Oncology20261 citationsOpen Access

DOI: 10.1200/jco.2026.44.7_suppl.344

Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma

Zarba M, Saad E, Semaan K, Zarif TE, Ferrier E, Wells C, Chehade REH, Basappa NS, Ebrahimi H, Huseni M

JAMA Network Open20261 citationsOpen Access

DOI: 10.1001/jamanetworkopen.2026.7030

Real-world management and clinical outcomes of first line treatment of advanced renal cell carcinoma in older patients in Canada

Curry L, Ghosh S, Arenovich E, Tanguay S, Lalani A-KA, Heng DYC, Bhindi B, Basappa NS, Graham J, Bjarnason GA

Journal of Geriatric Oncology20261 citations

DOI: 10.1016/j.jgo.2026.102905

Urologist-Level Variation in Androgen Deprivation Therapy Intensification in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective, Population-Based Cohort Study in Ontario, Canada

Berscheid K, Khosh Kish E, Satkunasivam R, Aminoltejari K, Hird A, Roy S, Morgan SC, Ong M, Jiang DM, Gotto G

20261 citationsOpen Access

DOI: 10.1097/ju9.0000000000000490

Forecasting Trends in Androgen Deprivation Therapy Intensification for Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Population-Based Cohort and Time-Series Analysis

Kish EK, Dvorani E, Saskin R, Wilton AS, Satkunasivam R, Aminoltejari K, Hird A, Berscheid K, Roy S, Morgan SC

Current Oncology20261 citationsOpen Access

DOI: 10.3390/curroncol33050276

Outcomes and Predictors of Recurrence and Survival in Surgically Resected Localized Chromophobe Renal Cell Carcinoma: Results from the Canadian Kidney Cancer Information System (CKCis)

Arenovich E, Breau R, Rendon R, Mallick R, Tanguay S, Pouliot F, Lavallee L, Feifer A, Finelli A, Bansal R

Current Oncology20261 citationsOpen Access

DOI: 10.3390/curroncol33030175

Prospective clinical activity and preclinical basis of panitumumab-based EGFR blockade in SMARCB1-deficient renal medullary carcinoma (RMC): A collaborative multi-institutional study.

Msaouel P, Rupe ES, Chen X, Kotecha RR, Rieke DT, McGregor BA, Daw NC, Fan AC, Knoche EM, Kyriakopoulos C

Journal of Clinical Oncology2026

DOI: 10.1200/jco.2026.44.16_suppl.4520

Urologist-level variation in androgen deprivation therapy intensification in patients with metastatic hormone-sensitive prostate cancer: A retrospective, population-based cohort study in Ontario, Canada.

Wallis CJD, Nguyen D-D, Berscheid K, Kish EK, Satkunasivam R, Aminoltejari K, Hird AE, Roy S, Morgan SC, Malone S

Journal of Clinical Oncology2026Senior author

DOI: 10.1200/jco.2026.44.7_suppl.59

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Alina Lalani

Research

Latest papers

Association Between Sociodemographic Marginalization and Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer: Population-Based Cohort Study in Ontario, Canada.

Use of concomitant G-CSF in maintaining efficacious dose and safe delivery of docetaxel in combination with darolutamide in ARASENS: A phase III study

Comparing NCCN-based risk groups to the PROTEUS definition of high-risk localized prostate cancer to inform peri-operative care.

Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma

Real-world management and clinical outcomes of first line treatment of advanced renal cell carcinoma in older patients in Canada

Urologist-Level Variation in Androgen Deprivation Therapy Intensification in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective, Population-Based Cohort Study in Ontario, Canada

Forecasting Trends in Androgen Deprivation Therapy Intensification for Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Population-Based Cohort and Time-Series Analysis

Outcomes and Predictors of Recurrence and Survival in Surgically Resected Localized Chromophobe Renal Cell Carcinoma: Results from the Canadian Kidney Cancer Information System (CKCis)

Prospective clinical activity and preclinical basis of panitumumab-based EGFR blockade in SMARCB1-deficient renal medullary carcinoma (RMC): A collaborative multi-institutional study.

Urologist-level variation in androgen deprivation therapy intensification in patients with metastatic hormone-sensitive prostate cancer: A retrospective, population-based cohort study in Ontario, Canada.

Frequent collaborators

Aly-Khan Lalani

Rodney Breau

Dominick Bossé

Antonio Finelli

Sunita Ghosh

Sebastien Hotte

Eric Winquist

Luke Lavallée

Ricardo Rendon

Michael Ong

Bobby Shayegan

Rahul Bansal

Christina Canil

Scott Morgan

Alan So

Anand Swaminath

Girish Kulkarni

Kim Chi

Srikala Sridhar

Gregory Pond

Ming Tsao

Nayyer Iqbal

Normand Blais

Georg Bjarnason

Denis Soulières

Guila Delouya

Fred Saad

Muhammad Salim

William Chu

Vincent Castonguay

Kristen McAlpine

Refik Saskin

Peter Chung